Channelpedia

Kv11.1 Channel

2538 automatically matched literature references

1

5

Su Z et al. Novel cell-free high-throughput screening method for pharmacological tools targeting K+ channels.
Proc. Natl. Acad. Sci. U.S.A., 2016 May 17 , 113 (5748-53).

9

Colatsky T et al. The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative - Update on progress.
J Pharmacol Toxicol Methods, 2016 Jun 6 , ().

10

Carbonell-Pascual B et al. Comparison between Hodgkin-Huxley and Markov formulations of cardiac ion channels.
J. Theor. Biol., 2016 Jun 21 , 399 (92-102).

11

Yamaguchi Y et al. Latent pathogenicity of the G38S polymorphism of KCNE1 K(+) channel modulator.
Heart Vessels, 2016 Jun 2 , ().

15

Wu W et al. Molecular Basis of Cardiac Delayed Rectifier Potassium Channel Function and Pharmacology.
Card Electrophysiol Clin, 2016 Jun , 8 (275-84).

24

Gintant G et al. Evolution of strategies to improve preclinical cardiac safety testing.
Nat Rev Drug Discov, 2016 Feb 19 , ().

31

Liu F et al. Cotranslational association of mRNA encoding subunits of heteromeric ion channels.
Proc. Natl. Acad. Sci. U.S.A., 2016 Apr 26 , 113 (4859-64).

33

Ichikawa M et al. Multigenerational Inheritance of Long QT Syndrome Type 2 in a Japanese Family.
Intern. Med., 2016 , 55 (259-62).

38

Hassinen M et al. Molecular basis and drug sensitivity of the delayed rectifier (IKr) in the fish heart.
Comp. Biochem. Physiol. C Toxicol. Pharmacol., 2015 Oct-Nov , 176-177 (44-51).

39

Arcangeli A et al. Novel perspectives in cancer therapy: Targeting ion channels.
Drug Resist. Updat., 2015 Jul-Aug , 21-22 (11-9).

42

González Cabrera D et al. Structure-Activity Relationship Studies of Orally Active Antimalarial 2,4-Diamino-thienopyrimidines.
J. Med. Chem., 2015 Sep 24 , 58 (7572-9).

50

Frea S et al. New echocardiographic insights in short QT syndrome: More than a channelopathy?
Heart Rhythm, 2015 Oct , 12 (2096-105).

51

Lees-Miller JP et al. In response to Melgari et al. "hERG potassium channel inhibition by ivabradine requires channel gating".
J. Mol. Cell. Cardiol., 2015 Oct , 87 (192-3).

52

Melgari D et al. hERG potassium channel inhibition by ivabradine requires channel gating.
J. Mol. Cell. Cardiol., 2015 Oct , 87 (126-8).

53

Lee HJ et al. Mechanism of inhibition by olanzapine of cloned hERG potassium channels.
Neurosci. Lett., 2015 Nov 16 , 609 (97-102).

56

Zhao H et al. Discovery of novel N-aryl piperazine CXCR4 antagonists.
Bioorg. Med. Chem. Lett., 2015 Nov 1 , 25 (4950-5).

57

Delaunois A et al. Cardiac safety of lacosamide: the non-clinical perspective.
Acta Neurol. Scand., 2015 Nov , 132 (337-45).

60

Leren IS et al. Cardiac Mechanical Alterations and Genotype Specific Differences in Subjects With Long QT Syndrome.
JACC Cardiovasc Imaging, 2015 May , 8 (501-10).

64

65

66

Perry MD et al. Getting to the heart of hERG K(+) channel gating.
J. Physiol. (Lond.), 2015 Mar 27 , ().

68

Goodchild SJ et al. Sequence of gating charge movement and pore gating in HERG activation and deactivation pathways.
Biophys. J., 2015 Mar 24 , 108 (1435-47).

69

71

Biliczki P et al. The interaction between delayed rectifier channel alpha-subunits does not involve hetero-tetramer formation.
Naunyn Schmiedebergs Arch. Pharmacol., 2015 Mar 20 , ().

73

75

Han SN et al. [Effects of midazolam on hERG K+ channel].
Zhongguo Ying Yong Sheng Li Xue Za Zhi, 2015 Mar , 31 (143-7).

76

Yang L et al. Intravenous anesthetic propofol inhibits multiple human cardiac potassium channels.
Anesthesiology, 2015 Mar , 122 (571-84).

77

82

Wu W et al. The Link between Inactivation and High-Affinity Block of hERG1 Channels.
Mol. Pharmacol., 2015 Jun , 87 (1042-50).

83

Zhao X et al. Up-regulation of miR-21 and miR-23a Contributes to As2 O3 -induced hERG Channel Deficiency.
Basic Clin. Pharmacol. Toxicol., 2015 Jun , 116 (516-23).

87

Stattin EL et al. Genetic screening in sudden cardiac death in the young can save future lives.
Int. J. Legal Med., 2015 Jul 31 , ().

88

Zhang W et al. Kcnh2 and Kcnj8 Interactively Regulate Skin Wound Healing and Regeneration.
Wound Repair Regen, 2015 Jul 28 , ().

89

Yue Y et al. Pathogenesis of the Novel Autoimmune-Associated Long-QT Syndrome.
Circulation, 2015 Jul 28 , 132 (230-40).

91

Lee S et al. Cellular mechanisms for trazodone-induced cardiotoxicity.
Hum Exp Toxicol, 2015 Jul 17 , ().

97

Issa NP et al. QT interval prolongation in a patient with LQT2 on levetiracetam.
Seizure, 2015 Jul , 29 (134-6).

100

Wiśniowska B et al. Enhanced QSAR models for drug-triggered inhibition of the main cardiac ion currents.
J Appl Toxicol, 2015 Jan 5 , ().

102

Vedani A et al. OpenVirtualToxLab--a platform for generating and exchanging in silico toxicity data.
Toxicol. Lett., 2015 Jan 22 , 232 (519-32).

103

Saber S et al. Complex genetic background in a large family with Brugada syndrome.
Physiol Rep, 2015 Jan 1 , 3 ().

104

Lynch SM et al. N-Aryl azacycles as novel sodium channel blockers.
Bioorg. Med. Chem. Lett., 2015 Jan 1 , 25 (48-52).

108

Riuró H et al. Genetic analysis, in silico prediction, and family segregation in long QT syndrome.
Eur. J. Hum. Genet., 2015 Jan , 23 (79-85).

110

Chae YJ et al. Effects of donepezil on hERG potassium channels.
Brain Res., 2015 Feb 9 , 1597 (77-85).

114

Männikkö R et al. Pharmacological and electrophysiological characterisation of hERG activator AZSMO-23.
Br. J. Pharmacol., 2015 Feb 12 , ().

116

Vijayvergiya V et al. Single channel and ensemble hERG conductance measured in droplet bilayers.
Biomed Microdevices, 2015 Feb , 17 (12).

126

127

Sviripa VM et al. Par-4 secretion: stoichiometry of 3-arylquinoline binding to vimentin.
Org. Biomol. Chem., 2015 Dec 15 , 14 (74-84).

128

Sundby E et al. In vitro baselining of new pyrrolopyrimidine EGFR-TK inhibitors with Erlotinib.
Eur J Pharm Sci, 2015 Dec 1 , 80 (56-65).

131

Liang D et al. [Expression of human ether-a-go-go-related gene in laryngeal carcinoma].
Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, 2015 Dec , 29 (2160-3).

132

134

Chen J et al. Rab11-dependent Recycling of the Human Ether-a-go-go-related Gene (hERG) Channel.
J. Biol. Chem., 2015 Aug 21 , 290 (21101-13).

139

141

142

Zhang J et al. [Effects of allitridum on rapidly delayed rectifier potassium current in HEK293 cell line].
Nan Fang Yi Ke Da Xue Xue Bao, 2015 Aug , 35 (1128-32, 1142).

146

Osterbur ML et al. An Interdomain KCNH2 Mutation Produces an Intermediate Long QT Syndrome.
Hum. Mutat., 2015 Aug , 36 (764-73).

147

Zhang C et al. Identification of Low-Risk Adult Congenital LQTS Patients.
J. Cardiovasc. Electrophysiol., 2015 Aug , 26 (853-8).

150

Chae YJ et al. Endoxifen, the active metabolite of tamoxifen, inhibits cloned hERG potassium channels.
Eur. J. Pharmacol., 2015 Apr 5 , 752 (1-7).

153

Ferreiro SF et al. Acute cardiotoxicity evaluation of the marine biotoxins OA, DTX-1 and YTX.
Toxins (Basel), 2015 Apr , 7 (1030-47).

164

Pugsley MK et al. Biophysics and Molecular Biology of Cardiac Ion Channels for the Safety Pharmacologist.
Handb Exp Pharmacol, 2015 , 229 (149-203).

173

Jing Y et al. In silico prediction of hERG inhibition.
Future Med Chem, 2015 , 7 (571-86).

176

Giacomini E et al. A ligand-based virtual screening approach to identify small molecules as HERG channel activators.
Comb. Chem. High Throughput Screen., 2015 , 18 (269-80).

179

Lastraioli E et al. hERG1 Potassium Channels: Novel Biomarkers in Human Solid Cancers.
Biomed Res Int, 2015 , 2015 (896432).

180

Shi YQ et al. High Glucose Represses hERG K+ Channel Expression through Trafficking Inhibition.
Cell. Physiol. Biochem., 2015 , 37 (284-96).

182

Shi YQ et al. Mechanisms underlying probucol-induced hERG-channel deficiency.
Drug Des Devel Ther, 2015 , 9 (3695-704).

183

Martelli A et al. Inhibitors of the renal outer medullary potassium channel: a patent review.
Expert Opin Ther Pat, 2015 , 25 (1035-51).

186

Gibson JK et al. Human stem cell-derived cardiomyocytes detect drug-mediated changes in action potentials and ion currents.
J Pharmacol Toxicol Methods, 2014 Nov-Dec , 70 (255-67).

187

Mirams GR et al. Prediction of Thorough QT study results using action potential simulations based on ion channel screens.
J Pharmacol Toxicol Methods, 2014 Nov-Dec , 70 (246-54).

188

192

Brudeli B et al. Discovery and pharmacological profile of new hydrophilic 5-HT(4) receptor antagonists.
Bioorg. Med. Chem. Lett., 2014 Sep 15 , 24 (4598-602).

193

194

Bartok A et al. Margatoxin is a non-selective inhibitor of human Kv1.3 K(+) channels.
Toxicon, 2014 Sep , 87 (6-16).

198

Kim Y et al. Novel thienopyrimidinones as mGluR1 antagonists.
Eur J Med Chem, 2014 Oct 6 , 85 (629-37).

199

Kauthale RR et al. Assessment of temperature-induced hERG channel blockade variation by drugs.
J Appl Toxicol, 2014 Oct 28 , ().

200

Kratz JM et al. Experimentally validated HERG pharmacophore models as cardiotoxicity prediction tools.
J Chem Inf Model, 2014 Oct 27 , 54 (2887-901).

201

Perlmutter JI et al. Repurposing the antihistamine terfenadine for antimicrobial activity against Staphylococcus aureus.
J. Med. Chem., 2014 Oct 23 , 57 (8540-62).

203

204

Olde Nordkamp LR et al. Syncope in genotype-negative long QT syndrome family members.
Am. J. Cardiol., 2014 Oct 15 , 114 (1223-8).

205

Nogawa H et al. hERG trafficking inhibition in drug-induced lethal cardiac arrhythmia.
Eur. J. Pharmacol., 2014 Oct 15 , 741 (336-9).

206

Wu W et al. Cooperative subunit interactions mediate fast C-type inactivation of hERG1 K+ channels.
J. Physiol. (Lond.), 2014 Oct 15 , 592 (4465-80).

208

211

Linder T et al. Structural insights into trapping and dissociation of small molecules in K⁺ channels.
J Chem Inf Model, 2014 Nov 24 , 54 (3218-28).

212

Colenso CK et al. Voltage sensor gating charge transfer in a hERG potassium channel model.
Biophys. J., 2014 Nov 18 , 107 (L25-8).

216

222

Zhao X et al. The rescuable function and mechanism of resveratrol on As₂O₃-induced hERG K⁺ channel deficiency.
Naunyn Schmiedebergs Arch. Pharmacol., 2014 Nov , 387 (1079-89).

223

Frolov RV et al. Celecoxib and ion channels: a story of unexpected discoveries.
Eur. J. Pharmacol., 2014 May 5 , 730 (61-71).

227

Hill AP et al. Kinetics of drug interaction with the Kv11.1 potassium channel.
Mol. Pharmacol., 2014 May , 85 (769-76).

229

Wang Q et al. Gain-of-function KCNH2 mutations in patients with Brugada syndrome.
J. Cardiovasc. Electrophysiol., 2014 May , 25 (522-30).

233

236

Pond AL et al. The mERG1a channel modulates skeletal muscle MuRF1, but not MAFbx, expression.
Muscle Nerve, 2014 Mar , 49 (378-88).

238

Rodríguez-Ravelo R et al. A K⁺ channel blocking peptide from the Cuban scorpion Rhopalurus garridoi.
Peptides, 2014 Mar , 53 (42-7).

240

Koenig X et al. Anti-addiction drug ibogaine inhibits hERG channels: a cardiac arrhythmia risk.
Addict Biol, 2014 Mar , 19 (237-9).

243

Coleman N et al. New Positive KCa Channel Gating Modulators with Selectivity for KCa3.1.
Mol. Pharmacol., 2014 Jun 23 , ().

247

251

252

Sherhod R et al. Emerging pattern mining to aid toxicological knowledge discovery.
J Chem Inf Model, 2014 Jul 28 , 54 (1864-79).

255

Glengarry JM et al. Long QT molecular autopsy in sudden infant death syndrome.
Arch. Dis. Child., 2014 Jul , 99 (635-40).

256

Bando S et al. Congenital long QT syndrome with compound mutations in the KCNH2 gene.
Heart Vessels, 2014 Jul , 29 (554-9).

257

González Cabrera D et al. 2,4-Diaminothienopyrimidines as Orally Active Antimalarial Agents.
J. Med. Chem., 2014 Jan 28 , ().

258

Radresa O et al. Roles of PKC Isoforms in PMA-Induced Modulation of the hERG Channel (Kv11.1).
J Biomol Screen, 2014 Jan 24 , ().

259

Gohlke BO et al. SuperPain--a resource on pain-relieving compounds targeting ion channels.
Nucleic Acids Res., 2014 Jan 1 , 42 (D1107-12).

268

271

Thurner P et al. Mechanism of hERG channel block by the psychoactive indole alkaloid ibogaine.
J. Pharmacol. Exp. Ther., 2014 Feb , 348 (346-58).

272

Zhang Y et al. The SCN5A mutation A1180V is associated with electrocardiographic features of LQT3.
Pediatr Cardiol, 2014 Feb , 35 (295-300).

273

Ferreiro SF et al. In vivo arrhythmogenicity of the marine biotoxin azaspiracid-2 in rats.
Arch. Toxicol., 2014 Feb , 88 (425-34).

274

Roder K et al. RING finger protein RNF207, a novel regulator of cardiac excitation.
J. Biol. Chem., 2014 Dec 5 , 289 (33730-40).

275

Jones DK et al. hERG 1b is critical for human cardiac repolarization.
Proc. Natl. Acad. Sci. U.S.A., 2014 Dec 16 , 111 (18073-7).

277

Lim CJ et al. Synthesis and SAR of thieno[3,2-b]pyridinyl urea derivatives as urotensin-II receptor antagonists.
Bioorg. Med. Chem. Lett., 2014 Dec 15 , 24 (5832-5).

281

Strauss KA et al. A population-based study of KCNH7 p.Arg394His and bipolar spectrum disorder.
Hum. Mol. Genet., 2014 Dec 1 , 23 (6395-406).

282

Li P et al. The human ether-a-go-go-related gene activator NS1643 enhances epilepsy-associated KCNQ channels.
J. Pharmacol. Exp. Ther., 2014 Dec , 351 (596-604).

283

Lin EC et al. Mouse ERG K(+) channel clones reveal differences in protein trafficking and function.
J Am Heart Assoc, 2014 Dec , 3 (e001491).

285

289

Schmidtke P et al. Dynamics of hERG closure allow novel insights into hERG blocking by small molecules.
J Chem Inf Model, 2014 Aug 25 , 54 (2320-33).

291

294

295

Hajj A et al. KCNH2 polymorphism and methadone dosage interact to enhance QT duration.
Drug Alcohol Depend, 2014 Aug 1 , 141 (34-8).

297

Liu LL et al. Novel Bayesian classification models for predicting compounds blocking hERG potassium channels.
Acta Pharmacol. Sin., 2014 Aug , 35 (1093-102).

299

Gong Q et al. Identification of Kv11.1 isoform switch as a novel pathogenic mechanism of long-QT syndrome.
Circ Cardiovasc Genet, 2014 Aug , 7 (482-90).

300

Martinson AS et al. Functional evolution of Erg potassium channel gating reveals an ancient origin for IKr.
Proc. Natl. Acad. Sci. U.S.A., 2014 Apr 15 , 111 (5712-7).

303

Wang D et al. Cardiac channelopathy testing in 274 ethnically diverse sudden unexplained deaths.
Forensic Sci. Int., 2014 Apr , 237 (90-9).

304

Sanguinetti MC HERG1 channel agonists and cardiac arrhythmia.
Curr Opin Pharmacol, 2014 Apr , 15 (22-7).

305

Heijman J et al. Cardiac safety assays.
Curr Opin Pharmacol, 2014 Apr , 15 (16-21).

306

Chanséaume A et al. [KCNH2 gene new mutation in a patient with prior diagnosis of epilepsy].
Rev. Neurol. (Paris), 2014 Apr , 170 (304-5).

307

Wu W et al. Stoichiometry of altered hERG1 channel gating by small molecule activators.
J. Gen. Physiol., 2014 Apr , 143 (499-512).

308

Silvestre JS et al. Evidence for a crucial modulating role of the sodium channel in the QTc prolongation related to antipsychotics.
J. Psychopharmacol. (Oxford), 2014 Apr , 28 (329-40).

309

Noriega-Navarro R et al. Novel TASK channels inhibitors derived from dihydropyrrolo[2,1-a]isoquinoline.
Neuropharmacology, 2014 Apr , 79 (28-36).

310

Tester DJ et al. GENETICS OF LONG QT SYNDROME.
Methodist Debakey Cardiovasc J, 2014 1 , 10 (29-33).

318

Munoz C et al. Up-regulation of Kir2.1 (KCNJ2) by the serum & glucocorticoid inducible SGK3.
Cell. Physiol. Biochem., 2014 , 33 (491-500).

319

Shao XD et al. The mechanism of COX-2 regulating HERG channel in gastric cancer cells.
Bratisl Lek Listy, 2014 , 115 (487-91).

321

Shimizu W Clinical and genetic diagnosis for inherited cardiac arrhythmias.
J Nippon Med Sch, 2014 , 81 (203-10).

322

Liu J et al. Patch-clamp technique in ESC-derived cardiomyocytes.
Methods Mol. Biol., 2014 , 1181 (203-14).

324

Braga RC et al. Tuning HERG out: antitarget QSAR models for drug development.
Curr Top Med Chem, 2014 , 14 (1399-415).

331

Pakladok T et al. Up-regulation of hERG K⁺ channels by B-RAF.
PLoS ONE, 2014 , 9 (e87457).

334

Sanders NG et al. Antimalarial efficacy of hydroxyethylapoquinine (SN-119) and its derivatives.
Antimicrob. Agents Chemother., 2014 , 58 (820-7).

335

Goodchild SJ et al. Gating charge movement precedes ionic current activation in hERG channels.
Channels (Austin), 2014 , 8 (84-9).

341

Lee SH et al. Blockade of HERG human K+ channels by the antidepressant drug paroxetine.
Biol. Pharm. Bull., 2014 , 37 (1495-504).

342

Zhang K et al. Berberine induces hERG channel deficiency through trafficking inhibition.
Cell. Physiol. Biochem., 2014 , 34 (691-702).

349

Zeng H et al. Halide Ion Effects on Human Ether-à-go-go Related Gene Potassium Channel Properties.
Assay Drug Dev Technol, 2013 Nov-Dec , 11 (544-50).

351

Elkins RC et al. Variability in high-throughput ion-channel screening data and consequences for cardiac safety assessment.
J Pharmacol Toxicol Methods, 2013 Jul-Aug , 68 (112-22).

352

Morissette P et al. The anesthetized guinea pig: An effective early cardiovascular derisking and lead optimization model.
J Pharmacol Toxicol Methods, 2013 Jul-Aug , 68 (137-49).

354

Rampe D et al. A history of the role of the hERG channel in cardiac risk assessment.
J Pharmacol Toxicol Methods, 2013 Jul-Aug , 68 (13-22).

356

Chun YS et al. Cholesterol regulates HERG K+ channel activation by increasing phospholipase C β1 expression.
Channels (Austin), 2013 Jul-Aug , 7 (275-87).

358

Haugaa KH et al. Abnormal electroencephalograms in patients with long QT syndrome.
Heart Rhythm, 2013 Sep 27 , ().

359

Czodrowski P hERG me out.
J Chem Inf Model, 2013 Sep 23 , 53 (2240-51).

362

363

Haitin Y et al. The structural mechanism of KCNH-channel regulation by the eag domain.
Nature, 2013 Sep 19 , 501 (444-8).

366

Cordeiro JM et al. Developmental changes in expression and biophysics of ion channels in the canine ventricle.
J. Mol. Cell. Cardiol., 2013 Sep 10 , 64C (79-89).

371

373

Zhang P et al. Blockade of the human ether-a-go-go-related gene potassium channel by ketamine.
J. Pharm. Pharmacol., 2013 Sep , 65 (1321-8).

374

Fischer F et al. Acute and subacute effects of the selective serotonin-noradrenaline reuptake inhibitor duloxetine on cardiac hERG channels.
Naunyn Schmiedebergs Arch. Pharmacol., 2013 Sep , 386 (795-804).

375

Nawathe PA et al. An LQTS6 MiRP1 mutation suppresses pacemaker current and is associated with sinus bradycardia.
J. Cardiovasc. Electrophysiol., 2013 Sep , 24 (1021-7).

378

Meng J et al. Compound ICA-105574 prevents arrhythmias induced by cardiac delayed repolarization.
Eur. J. Pharmacol., 2013 Oct 15 , 718 (87-97).

380

Salyer SA et al. Vacuolar ATPase driven potassium transport in highly metastatic breast cancer cells.
Biochim. Biophys. Acta, 2013 Oct , 1832 (1734-43).

381

Andreasen L et al. Genetic Modifier of the QTc Interval Associated With Early-Onset Atrial Fibrillation.
Can J Cardiol, 2013 Oct , 29 (1234-40).

383

Yoshinaga M et al. Electrocardiographic screening of 1-month-old infants for identifying prolonged QT intervals.
Circ Arrhythm Electrophysiol, 2013 Oct , 6 (932-8).

385

Lee YS et al. Long QT syndrome: a Korean single center study.
J. Korean Med. Sci., 2013 Oct , 28 (1454-60).

386

Fiore A et al. Characterization of hERG1 channel role in mouse colorectal carcinogenesis.
Cancer Med, 2013 Oct , 2 (583-94).

388

392

Stump MR et al. LQT2 nonsense mutations generate trafficking defective NH2-terminally truncated channels by the reinitiation of translation.
Am. J. Physiol. Heart Circ. Physiol., 2013 Nov 1 , 305 (H1397-404).

397

Almilaji A et al. AMP-activated protein kinase regulates hERG potassium channel.
Pflugers Arch., 2013 Nov , 465 (1573-82).

403

Mitton-Fry MJ et al. Novel quinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV.
Bioorg. Med. Chem. Lett., 2013 May 15 , 23 (2955-61).

404

Leifert A et al. Differential hERG ion channel activity of ultrasmall gold nanoparticles.
Proc. Natl. Acad. Sci. U.S.A., 2013 May 14 , 110 (8004-9).

405

de la Peña P et al. Mapping of interactions between the N- and C-termini and the channel core in HERG K+ channels.
Biochem. J., 2013 May 1 , 451 (463-74).

411

Aziz PF et al. Do LQTS gene single nucleotide polymorphisms alter QTc intervals at rest and during exercise stress testing?
Ann Noninvasive Electrocardiol, 2013 May , 18 (288-93).

415

416

Babcock JJ et al. hERG channel function: beyond long QT.
Acta Pharmacol. Sin., 2013 Mar , 34 (329-35).

419

Hashimoto R et al. The KCNH2 gene is associated with neurocognition and the risk of schizophrenia.
World J. Biol. Psychiatry, 2013 Mar , 14 (114-20).

421

Munoz C et al. Klotho sensitivity of the hERG channel.
FEBS Lett., 2013 Jun 5 , 587 (1663-8).

422

Steinke K et al. Coxsackievirus B3 modulates cardiac ion channels.
FASEB J., 2013 Jun 27 , ().

425

Ginman T et al. Core refinement toward permeable β-secretase (BACE-1) inhibitors with low hERG activity.
J. Med. Chem., 2013 Jun 13 , 56 (4181-205).

426

Wang S et al. Recent developments in computational prediction of HERG blockage.
Curr Top Med Chem, 2013 Jun 1 , 13 (1317-26).

429

Townsend C et al. Predicting Drug-Induced QT Prolongation and Torsades de Pointes: A Review of Preclinical Endpoint Measures.
Curr Protoc Pharmacol, 2013 Jun , Chapter 10 (Unit10.16).

435

Stowasser M Primary aldosteronism and potassium channel mutations.
Curr Opin Endocrinol Diabetes Obes, 2013 Jun , 20 (170-9).

436

Arcangeli A et al. High hERG1 expression in advanced melanoma.
Melanoma Res., 2013 Jun , 23 (185-90).

437

Brelidze TI et al. Structure of the C-terminal region of an ERG channel and functional implications.
Proc. Natl. Acad. Sci. U.S.A., 2013 Jul 9 , 110 (11648-53).

438

Nilsson MF et al. Comparative effects of sodium channel blockers in short term rat whole embryo culture.
Toxicol. Appl. Pharmacol., 2013 Jul 8 , ().

443

Takanari H et al. Efficient and specific cardiac IK1 inhibition by a new pentamidine analogue.
Cardiovasc. Res., 2013 Jul 1 , 99 (203-14).

444

Ryu S et al. The synergic modeling for the binding of fluoroquinolone antibiotics to the hERG potassium channel.
Bioorg. Med. Chem. Lett., 2013 Jul 1 , 23 (3848-51).

447

Rayan A et al. Indexing molecules for their hERG liability.
Eur J Med Chem, 2013 Jul , 65 (304-14).

451

Di Martino GP et al. An automated docking protocol for hERG channel blockers.
J Chem Inf Model, 2013 Jan 28 , 53 (159-75).

452

453

Di Veroli GY et al. High-throughput screening of drug-binding dynamics to HERG improves early drug safety assessment.
Am. J. Physiol. Heart Circ. Physiol., 2013 Jan 1 , 304 (H104-17).

455

Narayana Moorthy NS et al. Human ether-a-go-go-related gene channel blockers and its structural analysis for drug design.
Curr Drug Targets, 2013 Jan 1 , 14 (102-13).

461

Zarzoso M et al. Mission possible: RNA interference rescues the hERG current.
Heart Rhythm, 2013 Jan , 10 (137-8).

464

Ng CA et al. Insights into hERG K+ channel structure and function from NMR studies.
Eur. Biophys. J., 2013 Jan , 42 (71-9).

465

Wei T et al. [Effect of berberine, liensinine and neferine on HERG channel expression].
Zhongguo Zhong Yao Za Zhi, 2013 Jan , 38 (239-44).

469

Hausammann GJ et al. Generation of an antibody toolbox to characterize hERG.
Biochem. Biophys. Res. Commun., 2013 Feb 1 , 431 (70-5).

471

Silva D et al. Novel mutation in the KCNH2 gene associated with long QT syndrome.
Rev Port Cardiol, 2013 Feb , 32 (163-4).

472

Gustina AS et al. The eag domain regulates hERG channel inactivation gating via a direct interaction.
J. Gen. Physiol., 2013 Feb , 141 (229-41).

474

Dong H et al. Functional expression of ERG1 potassium channels in rat alveolar macrophages.
J. Mol. Histol., 2013 Feb , 44 (117-24).

475

Harris RA et al. Human metastable epiallele candidates link to common disorders.
Epigenetics, 2013 Feb , 8 (157-63).

476

Yang LJ et al. New targets for the antitumor activity of gambogic acid in hematologic malignancies.
Acta Pharmacol. Sin., 2013 Feb , 34 (191-8).

477

Hausammann GJ et al. Chimeric hERG channels containing a tetramerization domain are functional and stable.
Biochemistry, 2013 Dec 23 , 52 (9237-45).

478

Shi YP et al. External protons destabilize the activated voltage sensor in hERG channels.
Eur. Biophys. J., 2013 Dec 21 , ().

482

486

Goineau S et al. In vitro safety cardiovascular pharmacology studies: impact of formulation preparation and analysis.
Regul. Toxicol. Pharmacol., 2013 Dec , 67 (499-505).

487

Lin J et al. [Protein tyrosine phosphatase non-receptor type 12 negatively regulates cardiac HERG channel currents].
Nan Fang Yi Ke Da Xue Xue Bao, 2013 Dec , 33 (1718-22).

490

Hayashi M et al. Molecular basis of potassium channels in pancreatic duct epithelial cells.
Channels (Austin), 2013 Aug 20 , 7 ().

493

Sun H et al. Are hERG channel blockers also phospholipidosis inducers?
Bioorg. Med. Chem. Lett., 2013 Aug 15 , 23 (4587-90).

494

Kruse M et al. The phosphoinositide sensitivity of the KV channel family.
Channels (Austin), 2013 Aug 1 , 7 ().

500

504

Crotti L et al. Long QT syndrome-associated mutations in intrauterine fetal death.
JAMA, 2013 Apr 10 , 309 (1473-82).

506

Islas LD The electric heart of hERG.
J. Gen. Physiol., 2013 Apr , 141 (409-11).

507

He FZ et al. Current pharmacogenomic studies on hERG potassium channels.
Trends Mol Med, 2013 Apr , 19 (227-38).

515

Ouadid-Ahidouch H et al. K(+) channels and cell cycle progression in tumor cells.
Front Physiol, 2013 , 4 (220).

516

Moric-Janiszewska E et al. Quantitative PCR as an Alternative in the Diagnosis of Long-QT Syndrome.
Biomed Res Int, 2013 , 2013 (418604).

518

Adaixo R et al. Structural properties of PAS domains from the KCNH potassium channels.
PLoS ONE, 2013 , 8 (e59265).

520

521

Springer C et al. A fingerprint pair analysis of hERG inhibition data.
Chem Cent J, 2013 , 7 (167).

527

Pakladok T et al. PIKfyve sensitivity of hERG channels.
Cell. Physiol. Biochem., 2013 , 31 (785-94).

528

Thai KM et al. Pharmacophore modeling for antitargets.
Curr Top Med Chem, 2013 , 13 (1002-14).

530

Karnik R et al. Endocytosis of HERG is clathrin-independent and involves arf6.
PLoS ONE, 2013 , 8 (e85630).

542

547

Zumhagen S et al. Inherited long QT syndrome: clinical manifestation, genetic diagnostics, and therapy.
Herzschrittmacherther Elektrophysiol, 2012 Sep , 23 (211-9).

551

Kapoor A et al. Human cytomegalovirus inhibition by cardiac glycosides: evidence for involvement of the HERG gene.
Antimicrob. Agents Chemother., 2012 Sep , 56 (4891-9).

553

Bhattarai D et al. Synthesis and in vitro antibacterial activity of novel 3-azabicyclo[3.3.0]octanyl oxazolidinones.
Chem Biol Drug Des, 2012 Sep , 80 (388-97).

554

Lee SH et al. Blockade of human HERG K⁺ channels by rosiglitazone, an antidiabetic drug.
Arch. Pharm. Res., 2012 Sep , 35 (1655-64).

555

558

Abderemane-Ali F et al. Dual effect of phosphatidyl (4,5)-bisphosphate PIP2 on Shaker K+ channels.
J. Biol. Chem., 2012 Oct 19 , 287 (36158-67).

559

Procopiou PA et al. Synthesis and pharmacological investigation of azaphthalazinone human histamine H(1) receptor antagonists.
Bioorg. Med. Chem., 2012 Oct 15 , 20 (6097-108).

560

Högberg T et al. Melanin concentrating hormone receptor 1 (MCHR1) antagonists-Still a viable approach for obesity treatment?
Bioorg. Med. Chem. Lett., 2012 Oct 1 , 22 (6039-47).

563

Lee HA et al. Wide spectrum of inhibitory effects of sertraline on cardiac ion channels.
Korean J. Physiol. Pharmacol., 2012 Oct , 16 (327-32).

569

572

Dong Q et al. Blocking of the human ether-à-go-go-related gene channel by imatinib mesylate.
Biol. Pharm. Bull., 2012 Nov 30 , ().

573

Sherhod R et al. Automating knowledge discovery for toxicity prediction using jumping emerging pattern mining.
J Chem Inf Model, 2012 Nov 26 , 52 (3074-87).

574

Portonovo SA et al. hERG drug response measured in droplet bilayers.
Biomed Microdevices, 2012 Nov 18 , ().

576

Bahl A et al. The discovery of CCR3/H1 dual antagonists with reduced hERG risk.
Bioorg. Med. Chem. Lett., 2012 Nov 1 , 22 (6688-93).

579

Kam YL et al. HYP-1, a novel diamide compound, relieves inflammatory and neuropathic pain in rats.
Pharmacol. Biochem. Behav., 2012 Nov , 103 (33-42).

580

581

Edelmann J et al. Long QT syndrome mutation detection by SNaPshot technique.
Int. J. Legal Med., 2012 Nov , 126 (969-73).

587

Tang H et al. Discovery of Selective Small Molecule ROMK Inhibitors as Potential New Mechanism Diuretics.
ACS Med Chem Lett, 2012 May 10 , 3 (367-72).

589

Jiménez-Vargas JM et al. Interacting sites of scorpion toxin ErgTx1 with hERG1 K+ channels.
Toxicon, 2012 May , 59 (633-41).

590

Boström J et al. Oxadiazoles in medicinal chemistry.
J. Med. Chem., 2012 Mar 8 , 55 (1817-30).

595

Hanrahan P et al. Substituted azaquinazolinones as modulators of GHSr-1a for the treatment of type II diabetes and obesity.
Bioorg. Med. Chem. Lett., 2012 Mar 15 , 22 (2271-8).

596

Lacombe P et al. 3,4-Diarylpiperidines as potent renin inhibitors.
Bioorg. Med. Chem. Lett., 2012 Mar 1 , 22 (1953-7).

597

598

Bregman H et al. The discovery of aminopyrazines as novel, potent Na(v)1.7 antagonists: hit-to-lead identification and SAR.
Bioorg. Med. Chem. Lett., 2012 Mar 1 , 22 (2033-42).

603

Kaddar N et al. Tizanidine (Zanaflex): a muscle relaxant that may prolong the QT interval by blocking IKr.
J. Cardiovasc. Pharmacol. Ther., 2012 Mar , 17 (102-9).

604

Peterson LB et al. The hERG channel is dependent upon the Hsp90α isoform for maturation and trafficking.
Mol. Pharm., 2012 Jun 4 , 9 (1841-6).

605

607

Pérez-Victoria I et al. Isolation and structural elucidation of cyclic tetrapeptides from Onychocola sclerotica.
J. Nat. Prod., 2012 Jun 22 , 75 (1210-4).

610

Pajouhesh H et al. Structure-activity relationships of trimethoxybenzyl piperazine N-type calcium channel inhibitors.
Bioorg. Med. Chem. Lett., 2012 Jun 15 , 22 (4153-8).

611

Guo J et al. A422T mutation in HERG potassium channel retained in ER is rescurable by pharmacologic or molecular chaperones.
Biochem. Biophys. Res. Commun., 2012 Jun 1 , 422 (305-10).

612

613

Zhao J et al. Inhibitory effects of a bisbenzylisoquinline alkaloid dauricine on HERG potassium channels.
J Ethnopharmacol, 2012 Jun 1 , 141 (685-91).

614

Gönczi M et al. Age-dependent changes in ion channel mRNA expression in canine cardiac tissues.
Gen. Physiol. Biophys., 2012 Jun , 31 (153-62).

616

Van Slyke AC et al. Proton block of the pore underlies the inhibition of hERG cardiac K+ channels during acidosis.
Am. J. Physiol., Cell Physiol., 2012 Jun , 302 (C1797-806).

621

De Conti L et al. Complexities of 5'splice site definition: implications in clinical analyses.
RNA Biol, 2012 Jun , 9 (911-23).

623

Kulzer M et al. Inhibition of cardiac Kir2.1-2.3 channels by beta3 adrenoreceptor antagonist SR 59230A.
Biochem. Biophys. Res. Commun., 2012 Jul 27 , 424 (315-20).

625

Hayashi M et al. An intermediate-conductance Ca2+-activated K+ channel is important for secretion in pancreatic duct cells.
Am. J. Physiol., Cell Physiol., 2012 Jul 15 , 303 (C151-9).

630

Vandenberg JI et al. hERG K(+) channels: structure, function, and clinical significance.
Physiol. Rev., 2012 Jul , 92 (1393-478).

636

Sroubek J et al. The use of Bcl-2 over-expression to stabilize hybridomas specific to the HERG potassium channel.
J. Immunol. Methods, 2012 Jan 31 , 375 (215-22).

637

Hu CW et al. Curcumin inhibits hERG potassium channels in vitro.
Toxicol. Lett., 2012 Jan 25 , 208 (192-6).

639

Nguyen HN et al. Discovery and optimization of aminopyrimidinones as potent and state-dependent Nav1.7 antagonists.
Bioorg. Med. Chem. Lett., 2012 Jan 15 , 22 (1055-60).

640

McCauley JP et al. Multiparameter exploration of piperazine derivatives as δ-opioid receptor agonists for CNS indications.
Bioorg. Med. Chem. Lett., 2012 Jan 15 , 22 (1169-73).

641

Sundar BG et al. Novel brain penetrant benzofuropiperidine 5-HT₆ receptor antagonists.
Bioorg. Med. Chem. Lett., 2012 Jan 1 , 22 (120-3).

643

El Harchi A et al. Molecular determinants of hERG potassium channel inhibition by disopyramide.
J. Mol. Cell. Cardiol., 2012 Jan , 52 (185-95).

645

Krishnan Y et al. Partially dominant mutant channel defect corresponding with intermediate LQT2 phenotype.
Pacing Clin Electrophysiol, 2012 Jan , 35 (3-16).

646

Huang X et al. Comparative effects of Guanfu base A and Guanfu base G on HERG K+ channel.
J. Cardiovasc. Pharmacol., 2012 Jan , 59 (77-83).

650

Yamakawa Y et al. Pharmacophore modeling for hERG channel facilitation.
Biochem. Biophys. Res. Commun., 2012 Feb 3 , 418 (161-6).

659

Dennis AT et al. Molecular determinants of pentamidine-induced hERG trafficking inhibition.
Mol. Pharmacol., 2012 Feb , 81 (198-209).

660

661

Baaklini I et al. The DNAJA2 substrate release mechanism is essential for chaperone-mediated folding.
J. Biol. Chem., 2012 Dec 7 , 287 (41939-54).

663

González Cabrera D et al. Structure-activity relationship studies of orally active antimalarial 3,5-substituted 2-aminopyridines.
J. Med. Chem., 2012 Dec 27 , 55 (11022-30).

664

Schweikart K et al. The effects of jaspamide on human cardiomyocyte function and cardiac ion channel activity.
Toxicol In Vitro, 2012 Dec 20 , 27 (745-751).

665

Ishii K et al. Endocytic regulation of voltage-dependent potassium channels in the heart.
J. Pharmacol. Sci., 2012 Dec 18 , 120 (264-9).

666

Organ-Darling LE et al. Interactions between hERG and KCNQ1 α-subunits are mediated by their C-termini and modulated by cAMP.
Am. J. Physiol. Heart Circ. Physiol., 2012 Dec 15 , ().

667

Tanis VM et al. Azabenzthiazole inhibitors of leukotriene A₄ hydrolase.
Bioorg. Med. Chem. Lett., 2012 Dec 15 , 22 (7504-11).

670

671

Warner B Genetic variation in KCNH2 and a unique hERG isoform in patients with schizophrenia: efficacy-safety link.
Am J Psychiatry, 2012 Dec 1 , 169 (1318; author reply 1318-9).

674

Peters MF et al. Evaluation of cellular impedance measures of cardiomyocyte cultures for drug screening applications.
Assay Drug Dev Technol, 2012 Dec , 10 (525-32).

675

Butini S et al. Discovery of potent inhibitors of human and mouse fatty acid amide hydrolases.
J. Med. Chem., 2012 Aug 9 , 55 (6898-915).

678

Liu Y et al. Effects of the natural flavone trimethylapigenin on cardiac potassium currents.
Biochem. Pharmacol., 2012 Aug 15 , 84 (498-506).

679

Twiner MJ et al. Marine Algal Toxin Azaspiracid Is an Open-State Blocker of hERG Potassium Channels.
Chem. Res. Toxicol., 2012 Aug 10 , ().

682

Kruse M et al. Regulation of voltage-gated potassium channels by PI(4,5)P2.
J. Gen. Physiol., 2012 Aug , 140 (189-205).

686

Krishnan Y et al. Mechanisms underlying the protein-kinase mediated regulation of the HERG potassium channel synthesis.
Biochim. Biophys. Acta, 2012 Aug , 1823 (1273-84).

687

Gustina AS et al. HERG potassium channel regulation by the N-terminal eag domain.
Cell. Signal., 2012 Aug , 24 (1592-8).

688

Jiménez-Vargas JM et al. Toxin modulators and blockers of hERG K(+) channels.
, 2012 Apr 5 , ().

690

Cavalli A et al. Computational design and discovery of "minimally structured" hERG blockers.
J. Med. Chem., 2012 Apr 26 , 55 (4010-4).

697

699

Ababneh D et al. Antidepressants Cause Bradycardia and Heart Block in GD 13 Rat Embryos In Vitro.
Birth Defects Res. B Dev. Reprod. Toxicol., 2012 Apr , 95 (184-93).

703

706

Cheng YM et al. Voltage-dependent gating of HERG potassium channels.
Front Pharmacol, 2012 , 3 (83).

713

Ceccarini L et al. Ion conduction through the hERG potassium channel.
PLoS ONE, 2012 , 7 (e49017).

716

Moreno C et al. Polyunsaturated Fatty acids modify the gating of kv channels.
Front Pharmacol, 2012 , 3 (163).

722

723

Lazarczyk MJ et al. Selective acquired long QT syndrome (saLQTS) upon risperidone treatment.
BMC Psychiatry, 2012 , 12 (220).

726

Munoz C et al. Stimulation of HERG channel activity by β-catenin.
PLoS ONE, 2012 , 7 (e43353).

727

Ferro F et al. Long-chain acylcarnitines regulate the hERG channel.
PLoS ONE, 2012 , 7 (e41686).

728

Köpfer DA et al. A molecular switch driving inactivation in the cardiac K+ channel HERG.
PLoS ONE, 2012 , 7 (e41023).

729

Moric-Janiszewska E et al. Molecular diagnostics of families with long-QT syndrome.
Cardiol J, 2012 , 19 (159-67).

731

Zhang GH et al. Cytocompatible performance of thermosensitive poly(N-isopropylacrylamide) nanoparticles.
J Biomater Sci Polym Ed, 2012 , 23 (1569-78).

732

Qu Y et al. hERG potency estimates based upon dose solution analysis: What have we learned?
J Pharmacol Toxicol Methods, 2011 Nov-Dec , 64 (251-7).

734

Champeroux P et al. A step towards characterisation of electrophysiological profile of torsadogenic drugs.
J Pharmacol Toxicol Methods, 2011 May-Jun , 63 (269-78).

736

Dennis AT et al. Antidepressant-induced ubiquitination and degradation of the cardiac potassium channel hERG.
J. Biol. Chem., 2011 Sep 30 , 286 (34413-25).

737

740

Abi-Gerges N et al. hERG subunit composition determines differential drug sensitivity.
Br. J. Pharmacol., 2011 Sep , 164 (419-32).

751

Wang RR et al. The effects of paeoniflorin monomer of a Chinese herb on cardiac ion channels.
Chin. Med. J., 2011 Oct , 124 (3105-11).

752

Tester DJ et al. Unexplained drownings and the cardiac channelopathies: a molecular autopsy series.
Mayo Clin. Proc., 2011 Oct , 86 (941-7).

757

Jeon SH et al. Effects of nortriptyline on QT prolongation: a safety pharmacology study.
Hum Exp Toxicol, 2011 Oct , 30 (1649-56).

768

Furutani K et al. A mechanism underlying compound-induced voltage shift in the current activation of hERG by antiarrhythmic agents.
Biochem. Biophys. Res. Commun., 2011 Nov 11 , 415 (141-6).

769

González Cabrera D et al. Novel orally active antimalarial thiazoles.
J. Med. Chem., 2011 Nov 10 , 54 (7713-9).

772

Bai YL et al. HIV Tat protein inhibits hERG K+ channels: a potential mechanism of HIV infection induced LQTs.
J. Mol. Cell. Cardiol., 2011 Nov , 51 (876-80).

776

Wiles JA et al. Selenophene-containing inhibitors of type IIA bacterial topoisomerases.
J. Med. Chem., 2011 May 12 , 54 (3418-25).

778

Xia M et al. Identification of quaternary ammonium compounds as potent inhibitors of hERG potassium channels.
Toxicol. Appl. Pharmacol., 2011 May 1 , 252 (250-8).

779

780

Schramm A et al. HERG channel inhibitors in extracts of Coptidis rhizoma.
Planta Med., 2011 May , 77 (692-7).

783

Ando F et al. Synergic effects of β-estradiol and erythromycin on hERG currents.
J. Membr. Biol., 2011 May , 241 (31-8).

784

Soma K et al. Abundant expression of KCNE1 in the left ventricle of the miniature pig.
Heart Vessels, 2011 May , 26 (353-6).

786

Luker T et al. Zwitterionic CRTh2 antagonists.
J. Med. Chem., 2011 Mar 24 , 54 (1779-88).

790

Gustina AS et al. hERG potassium channel gating is mediated by N- and C-terminal region interactions.
J. Gen. Physiol., 2011 Mar , 137 (315-25).

791

Sun Y et al. A novel mutation in the KCNH2 gene associated with short QT syndrome.
J. Mol. Cell. Cardiol., 2011 Mar , 50 (433-41).

792

797

805

Liu Y et al. The role of the 4''-hydroxyl on motilin agonist potency in the 9-dihydroerythromycin series.
Bioorg. Med. Chem. Lett., 2011 Jun 15 , 21 (3712-4).

809

Choi KH et al. hERG channel blockade by externally applied quaternary ammonium derivatives.
Biochim. Biophys. Acta, 2011 Jun , 1808 (1560-6).

810

Zhou PZ et al. Activation of human ether-a-go-go related gene (hERG) potassium channels by small molecules.
Acta Pharmacol. Sin., 2011 Jun , 32 (781-8).

811

Johansson A Recent progress in the discovery of melanin-concentrating hormone 1-receptor antagonists.
Expert Opin Ther Pat, 2011 Jun , 21 (905-25).

813

Vigneault P et al. Prolongation of cardiac ventricular repolarization under paliperidone: how and how much?
J. Cardiovasc. Pharmacol., 2011 Jun , 57 (690-5).

815

Tang G et al. Identification of a Novel Bacterial K(+) Channel.
, 2011 Jul 9 , ().

820

Boukharta L et al. Computer simulations of structure-activity relationships for HERG channel blockers.
Biochemistry, 2011 Jul 12 , 50 (6146-56).

824

Couderc JP et al. T-wave morphology abnormalities in benign, potent, and arrhythmogenic I(kr) inhibition.
Heart Rhythm, 2011 Jul , 8 (1036-43).

826

834

Han S et al. Fluconazole inhibits hERG K(+) channel by direct block and disruption of protein trafficking.
Eur. J. Pharmacol., 2011 Jan 10 , 650 (138-44).

838

Stump MR et al. Multiple splicing defects caused by hERG splice site mutation 2592+1G>A associated with long QT syndrome.
Am. J. Physiol. Heart Circ. Physiol., 2011 Jan , 300 (H312-8).

841

848

Du CY et al. Enhanced inhibitory effect of acidosis on hERG potassium channels that incorporate the hERG1b isoform.
Biochem. Biophys. Res. Commun., 2011 Feb 11 , 405 (222-7).

850

Hu C et al. Down-regulation of the human ether-a-go-go-related gene in rat cardiac hypertrophy.
Am. J. Med. Sci., 2011 Feb , 341 (119-25).

851

Staudacher I et al. hERG K+ channel-associated cardiac effects of the antidepressant drug desipramine.
Naunyn Schmiedebergs Arch. Pharmacol., 2011 Feb , 383 (119-39).

854

Zhu S et al. Molecular diversity and functional evolution of scorpion potassium channel toxins.
Mol. Cell Proteomics, 2011 Feb , 10 (M110.002832).

855

Bentzen BH et al. Pharmacological activation of Kv11.1 in transgenic long QT-1 rabbits.
J. Cardiovasc. Pharmacol., 2011 Feb , 57 (223-30).

856